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Biologic therapies target aberrant pathways in diseases including diabetes, cancer and autoimmune dis-
orders. Despite recent scientific advances, patient access to these agents can be limited. Biosimilars are
designed to be highly similar to the originator biologic, targeting the same biological pathways, with
comparable efficacy and safety. Biosimilars have the advantage of lower treatment costs, offering the
potential for increased clinical use and patient access. Several biosimilars are approved for clinical use in
the USA and Europe; however, there is a lack of awareness about biosimilars among healthcare providers
and patients. This overview of the scientific basis of biosimilars and current indications aim to enhance
discussions with patients and increase understanding of the role of biosimilars in individual treatment
plans.
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Targeted biological therapies have transformed the face of modern medicine, enhancing the treatment options
available in oncology, endocrinology, rheumatology, dermatology, cardiology and nephrology [1–4]. Despite their
impact on the treatment of many diseases, patient access to biologic agents may be restricted by healthcare authorities
with limited resources [5–8].
As patent portfolios for biologic agents are nearing end of term, competitor manufacturers are permitted by health
authorities to develop biosimilars to improve access to effective targeted agents for broader patient populations.
These drugs have the potential to expand the use of biologic treatments through decreased therapy costs and
increased patient access. The ultimate goal of biosimilars is to improve the efficiency of healthcare systems and
overall patient outcomes [9,10]. Biosimilars are agents that are required to be highly similar to the originator biologic
(reference product) in terms of safety, purity and efficacy [11,12]. The WHO has piloted an initiative to improve
access to biologic therapies in low-income countries starting with biosimilars for rituximab (anti-CD20 antibody)
for treatment of lymphoma and trastuzumab (anti-human EGFR2 antibody) for treatment of breast cancer [13].
To date, 35 biosimilars are marketed in Europe and seven biosimilars are currently licensed in the USA (Table 1)
with many proposed biosimilars currently in development. As patent portfolios on many monoclonal antibody
biologics are nearing end of term, the focus is moving from agents for supportive cancer care to developing
biosimilars for this large product class. However, complex manufacturing systems are needed to develop these
large, biological molecules, limiting their introduction to the biosimilar market to date [14,15]. Biosimilars for
rituximab and bevacizumab have now been approved and the market is set to expand with the growing number of
monoclonal antibody biosimilars in development [15]. In the era of biosimilars, there is a need to improve awareness
of these agents to facilitate discussions between healthcare providers and patients. For instance, an international
survey of patients and the general public found around half of patients diagnosed with a condition that could be
treated with biologic drugs had never heard of biosimilars [16]. Healthcare providers play a crucial role in shaping
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patients’ perception of biosimilars and can provide appropriate information and advice. Although many are aware
of biosimilars, they lack knowledge on current developments or the terminology associated with biosimilars [17,18].
Nevertheless, the majority of healthcare providers are interested in bridging this knowledge gap and incorporating
biosimilars into clinical practice [17]. This review aims to enhance the level of understanding of healthcare providers
on various aspects of biosimilars to better equip them when communicating with patients concerning treatment
with biosimilars.
Understanding biosimilars
In comparison to chemically synthesized small molecule drugs, biologic therapies (such as monoclonal antibodies)
are generated in biological systems and are therefore structurally complex and inherently more variable [19,20]. The
overall structure of a biologic drug is defined by its primary amino acid sequence. To qualify as a biosimilar, one
requirement is that the primary amino acid sequence must be identical to the originator biologic. Variations in the
higher order structure of the protein can impact the function, immunogenicity and efficacy of the biologic product,
so any differences in higher order protein structure between the biosimilar and originator biologic are extensively
analyzed to determine that they are not expected to be clinically relevant [19–21].
As manufacturing conditions for biosimilars are complex, the biochemical and higher order structural character-
istics of the biosimilar will not be identical to the originator biologic. This is in contrast to generic versions of small
molecule drugs, which have an identical structure, stability and purity to the originator. Biosimilars, therefore,
should not be considered as generic versions of biologic drugs [22].
Understanding that complexity and heterogeneity is inherent to all biologic drugs, and is not limited to biosimi-
lars, highlights that biosimilars are intrinsically no more variable than originator biologics and there is no impact on
the efficacy and safety of biosimilars compared with originator products [23]. A better awareness of the production
and manufacturing process of biosimilars may address common misconceptions, such as biosimilars being generic
versions of biologic drugs [23].
Biosimilar regulation: quality, safety & efficacy
To obtain regulatory approval, biosimilars must be ‘highly similar’ with regard to their structural and functional
characteristics, and have similar pharmacokinetic, efficacy and safety profiles compared with the originator bio-
logic [11,12,24]. As the manufacturing process is complex, biosimilars are ‘highly similar’ but not identical to the
originator biologic, thus the small molecule generic drug approval process cannot be applied to biosimilars [25,26].
Regulatory requirements for biosimilar approval are broadly consistent across regulatory agencies, such as the EMA
and US FDA [11,12]; however, each submission is generally assessed on a case-by-case basis. Biosimilar developers col-
laborate with regulatory agencies to establish the appropriate analytical, nonclinical and clinical studies required to
demonstrate biosimilarity and to establish the evidence base needed to support the approval of biosimilars [11,12,24].
Biosimilar approval is based on a rigorous stepwise process of comparison with the originator biologic (Figure 1).
In contrast to the development of biologic drugs, a considerable proportion of the evidence is based on structural
and physiochemical assessments of the biosimilar. The demonstration of high structural and functional similarity to
the originator biologic reduces the extent of additional nonclinical and clinical studies that must be performed [24].
The regulatory pathway for originator biologics includes an extensive clinical trial program to support approval.
For biosimilars, data from each step of the biosimilar regulatory pathway are considered important, comprising
analytical and preclinical data, comparative pharmacokinetics, and efficacy and safety in a relevant therapeutic
indication known as the totality of evidence [11,12,15,24–26].
Initially, analytical studies are performed to demonstrate structural similarity (i.e., identical amino acid sequence
and similar higher order structure) and functional similarity. If necessary, these are followed by animal studies to
assess in vivo bioactivity and toxicity [28]. Lastly, a tailored head-to-head clinical trial program is conducted to
compare the pharmacokinetics, clinical efficacy, clinical safety and immunogenicity of the biosimilar and originator
biologic. Aspects of the trial design, such as end points and sample size, may differ compared with those needed for
approval of the originator biologic [6,26]. While originator biologics are usually assessed in controlled trials designed
to show superiority [6,26], the purpose of biosimilar clinical trials is to establish proof of quality and similarity
regarding pharmacokinetics and efficacy. Biosimilar clinical trials are also designed to address any remaining
concerns about product-related differences between the biosimilar and the originator biologic [6,15,26].
Regulatory guidelines require that data from a number of comparative in vitro tests are supplied to assess any
potential differences in the activity of the biosimilar compared with the originator biologic [29]. The number of
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Development pathways
Standard biologics
Clinical studies
Clinical pharmacology
PK/PD
Nonclinical
Analytical
Clinical
studies
Confirm safety
and efficacy in a
disease population
(dose ranging not
necessary)
Clinical
pharmacology
PK/PD
Nonclinical
Analytical
Biosimilars
Figure 1. Summary of the biosimilar and standard biologic approval pathways.
PD: Pharmacodynamic; PK: Pharmacokinetic.
Adapted with permission from [27].
tests required will depend on the batch-to-batch variability of the biosimilar and originator biologic. Biosimilars
have the same dosing schedule and route of administration as the originator biologic; however, differences in the
formulation, presentation and method of administration of the biosimilar may be allowed if there is no effect
on the safety and efficacy of the drug [30]. Once the similarity of a biosimilar to its originator biologic has been
demonstrated, a biosimilar can be approved for use in other eligible clinical indications that the originator biologic
is approved for [31]. However, this extrapolation of safety and efficacy data is not automatically guaranteed; it is
based on the totality of the evidence supporting biosimilarity and scientific justification, in which substantiation
of the mechanism of action and pharmacokinetics, being the same across indications, are key components.
The term ‘interchangeability’ is widely used but can have a different meaning depending on the country and
jurisdiction, and is also often used incorrectly when the topic under discussion is actually ‘switching’. In the EU,
there is no regulatory definition of interchangeability and the term refers only ‘to the possibility of exchanging one
medicine for another medicine that is expected to have the same clinical effect’ [30]. EU member states set individual
policies on switching and other prescribing practices, and most countries have decided that automatic substitution
without the intervention of the prescriber is inappropriate for biologics, including biosimilars [32]. Interchangeability
is defined by statute in the USA to mean that ‘the biological product may be substituted for the reference product
without the intervention of the healthcare provider who prescribed the reference product’, and this would enable
pharmacy-mediated substitution, where state laws allow [33,34]. However, this requires an additional standard to
biosimilarity defined in the statute and the FDA is currently drafting guidance on Considerations in Demonstrating
Interchangeability with a Reference Product [34,35]. Consequently, to avoid confusion across geographies, we have
chosen to refer specifically to ‘switching’ and ‘substitution’ in this paper, to ensure consistency of language and
meaning.
As with all biologics, it is critical to monitor the safety of biosimilars on an ongoing basis after approval.
Thus, any additional specific safety monitoring for the originator biologic also applies to the biosimilar [6,15,26]. For
example, the British Society for Rheumatology Biologics Register collects information on the biosimilars Benepali R©,
Inflectra R© and Remsima R© to ensure that the data on adverse events are as robust as those collected for the originator
biologics [36]. The evidence available from both the regulatory assessment and postmarketing surveillance has shown
biosimilars to have comparable efficacy and safety profiles to the originator biologic products [10,37–44]. For example,
Retacrit R©, a biosimilar to Eprex R©, a human recombinant epoetin, has demonstrated efficacy in treating anemia
associated with chronic renal failure or chemotherapy for solid tumors, malignant lymphoma or multiple myeloma.
Up to May 2016, the estimated postmarketing exposure for EU-approved Retacrit R© was approximately 323,000
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Table 2. How biosimilars have expanded use in Europe.
Therapy area Volume per TD (2016/year before biosimilar entrance)
Referenced product only (%) Biosimilar and referenced
product (%)
Biosimilar accessible market
(%)
Total markets (%)
G-CSF -74 122 63 58
HGH -14 41 45 45
Anti-TNF -10 19 19 26
Fertility 2 16 8 10
EPO -37 66 4 7
Insulins 14 19 15 4
All products in these therapy areas, including biosimilars, are contributing to this increased patient access (TD), to varying degrees in each country.
EPO: Erythropoietin; G-CSF: Granulocyte-colony stimulating factor; HGH: Human growth hormone; TD: Treatment day.
Reproduced with permission from QuintilesIMS [51].
patient-years, and the safety profile is consistent with that seen for the originator biologic [45]. The safety and
efficacy of biosimilars for erythropoiesis-stimulating agents and granulocyte-colony stimulating factor (G-CSF) has
also been demonstrated in supportive cancer care in real-world clinical practice settings [38,46].
Although the data required for biosimilar approval differ from those required for originator biologics and small
molecule generic drugs, the same high standards of safety and efficacy still apply. This ensures that when used in
clinical practice, biosimilars are expected to be as safe and effective as the originator biologic. Providing information
on the development and regulatory approval pathway of biosimilars may help address common concerns patients
have surrounding the safety, efficacy and quality of biosimilars [16,23].
Expanding patient access
Biosimilars have the potential to expand patient access to biologic medicines as possible treatment options across a
number of life-threatening and chronic diseases. In addition, biosimilars could provide savings and efficiencies for
healthcare systems. However, these savings are not expected to be on the same level as those seen for generic drugs,
as these smaller chemical products are easier to characterize, and it is usually sufficient to demonstrate structural
and pharmacokinetic similarity to achieve regulatory approval [26]. Typically, production of a generic drug can take
3–5 years at a cost of US$1–5 million; this is in contrast to the 8–10 years it can take to develop a biosimilar
at an estimated cost of US$100–200 million [47]. Biosimilars are less costly to produce compared with originator
biologics as the development process is designed to establish bioequivalence to the originator product in a relevant
patient population, and it is not necessary to re-establish efficacy for every indication for which the originator
product is approved [48,49]. Additionally, the introduction of biosimilars at a lower price than the originator biologic
can promote price competition within the product market [48–51]. Following the introduction of biosimilars in
Europe, increased competition has not only affected the price of the originator biologic but also the product
class, resulting in a fall in average prices within the total market [51]. In 2016, compared with the price before the
corresponding biosimilar was available, reductions of 4–27% were reported in the following therapy areas: epoetins,
G-CSF, fertility, human growth hormone and anti-TNF [51]. In the USA, it has been projected that biosimilars
will lead to a US$44.2 billion reduction in biologic spending over a 10-year period, based on an estimated 35%
price reduction [48]. A budget analysis of the rituximab biosimilar CT-P10 in European countries has estimated
projected savings of €56.82 million over a 1-year period (for treatment of non-Hodgkin’s lymphoma and chronic
lymphocytic leukemia). This would expand patient access to rituximab treatment for an additional 2263 patients
with non-Hodgkin’s lymphoma and 1624 patients with chronic lymphocytic leukemia [52].
Although uptake varies by product class and country, the introduction of biosimilars has increased patient access
to therapies across whole product classes in Europe (Table 2) [51]. This increase, in use of both the biosimilar and
originator biologic, ranges from 16% for fertility drugs to 122% for G-CSFs [51]. In particular, the availability of
biosimilar G-CSF has led to increased G-CSF usage in both Sweden and the UK [38]. The benefits of biosimilars can
go beyond the potential for healthcare cost savings and can have an effect on patient treatment overall. Increased
access to treatment, due to the availability of biosimilars, may enable physicians to adhere more closely to clinical
treatment guidelines or result in patients receiving treatment earlier in the course of their disease [38]. For example,
in a retrospective cohort study following switching of patients from originator to biosimilar filgrastim, a higher
proportion of patients received treatment for primary prophylaxis in the biosimilar cohort than those in the
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originator filgrastim cohort [53]. Patients may also benefit from more detailed examination during treatment; for
example, therapeutic drug monitoring has been used in patients with inflammatory bowel disease to guide decisions
regarding treatment withdrawal or switching to biosimilars [54,55].
Talking to patients
Patients may have concerns about receiving or switching to biosimilar treatment; they may have questions about
how safe the biosimilar is, whether it will be as effective as the originator biologic or if the biosimilar delivery device
differs in design and use [16,23,56,57]. The impact of ‘nocebo’ effects, whereby negative expectations of treatment lead
to potentially worse outcomes, also needs to be considered by healthcare providers [58,59]. These effects are unrelated
to the pharmacology of the drug, in that patients may simply perceive that a drug is less expensive because it is less
effective [60]. Enhanced communication by healthcare providers, for example, using ‘soft skills’, can alleviate patient
concerns. This strategy has proved successful in patients switching to biosimilars, with fewer patients discontinuing
treatment compared with patients transitioning without an enhanced communication strategy [61]. The Danish
Rheumatism Association has designed a national program to reassure patients about the safety of biosimilars
by providing independent information to patients and healthcare providers, along with improved monitoring of
prescriptions, such as providing easier ways to report side effects [62]. In future, a patient representative from the
Danish Rheumatism Association will be included on working groups for national recommendations on biologic
drugs and biosimilars to ensure that patient perspectives are included [62]. A recent review of biosimilars suggests
that healthcare providers should not prevent patients from switching to treatment with biosimilars due to concerns
about potential risks, as these are outweighed by expanding patient access to treatment [63].
It is important that healthcare providers fully understand biosimilars so that they have an increased confidence
in prescribing them [17,64]. Various resources are currently available to assist with education regarding biosimilars
and to support discussions with patients (Table 3). These include: up-to-date evidence on the science behind
biosimilars, regulatory requirements, typical questions that patients may have about treatment, video discussions
with clinical experts and support from patient advocacy groups [16,23]. The American Society of Oncology and the
European Society for Medical Oncology have both issued position statements to guide healthcare providers on the
use of biosimilars in oncology settings [34,65]. Providing guidance for healthcare providers will ensure that decisions
on biosimilar treatment are in the best interests of patients.
Healthcare providers are encouraged to have open discussions with patients about biosimilars and avoid using
overly technical language and medical jargon [66,67]. In order to increase the acceptance of biosimilars, there is
still a need for further materials and policies to better inform healthcare providers and patients [64,68]. In our
opinion, it is important to increase awareness about ‘biosimilarity’ of the originator biologic and the biosimilar. The
basis for regulatory approval of biosimilars is in demonstrating similarity between short-term end points within a
narrow margin to avoid repetition of the costly and larger trials required for approval of the originator biologic.
Patients should understand this concept in order to avoid the perception of a biosimilar as an ‘inferior drug’.
Information should be provided in a consistent and clear manner across resources, with access/links to further
reading materials. Integration of biosimilars into national and local policies for prescribing medicines could lead to
improved education and awareness of biosimilars, allowing healthcare providers and patients to have more informed
discussions and share decision making about treatment with biosimilars.
Summary
Biologics have shaped the therapeutic approach to human disease. Introducing high-quality, safe and effective
biosimilars could potentially expand patient access to these important medicines by broadening the number of
treatment options available and providing savings to healthcare systems. Healthcare providers can have a large
impact on a patient’s perception of biosimilars, and are a key source of information and advice for patients. Full use
should be made of the many additional resources available, such as online educational materials and information
from patient associations, to help inform patients and facilitate discussions about biosimilars between patients and
healthcare providers.
Future perspective
There is a growing number of biosimilars of originator biologics receiving regulatory approval, or in the late stages
of development, in Europe and the USA. Healthcare providers will therefore increasingly encounter biosimilars as
potential treatment options to consider for their patients across a number of chronic or life-threatening diseases.
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The range of educational resources on biosimilars is also likely to increase, which could help healthcare providers to
become more confident when prescribing biosimilars. Improved educational resources and initiatives will increase
understanding and ensure the most appropriate use of biosimilars, with the likelihood of improved overall patient
outcomes, through increased access, and healthcare system benefits. This, in turn, will help healthcare providers
to be more fully informed when discussing an expanding range of options for patients starting or switching to
biosimilar treatment.
Executive summary
• Despite biologic therapies enhancing the range of available treatment options in a number of chronic diseases,
patient access to these therapies can be limited.
• Patent portfolios for biologic therapies are nearing end of term, permitting drug companies to develop
biosimilars.
• There is a lack of awareness, among both healthcare providers and patients, about treatment with biosimilars.
Understanding biosimilars
• Biosimilars are highly similar to the originator biologic in terms of safety, purity and efficacy.
• The primary amino acid sequence is required to be identical to the originator biologic; however, biochemical and
higher order structural characteristics of the biosimilar may be different, although these differences are not
considered to impact clinical efficacy and safety.
• Biosimilars are not generic versions of biologic drugs.
Biosimilar regulation: quality, safety & efficacy
• Biosimilar approval is based on assessment of the totality of the evidence: including analytical and preclinical
data, comparative pharmacokinetics, and efficacy and safety information.
• This stepwise regulatory approach ensures that biosimilars are expected to be as safe and effective as the
originator biologic when used in clinical practice.
Expanding patient access
• Through price competition in product markets and reduced development costs, biosimilars have the potential to
expand patient access by providing savings for healthcare systems.
Talking to patients
• Patients may have a number of concerns about starting or switching to biosimilar treatment.
• A wide range of educational resources is available to improve awareness of biosimilars.
Summary
• Healthcare providers are a key source of information and advice for patients and have an important role in
determining a patient’s perception of biosimilars.
• Improved awareness of biosimilars could lead to more effective and better informed discussions between
healthcare providers and patients on patient treatment plans.
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